Loading stock dossier…
Lotus Eye Hospital and Institute Limited is a mid-cap Healthcare stock. The composite smart-money score (insider + FII/DII flow + block deals + mutual-fund accumulation) is currently in the "NEUTRAL" bucket.
Up to 10 years of daily closes, with vertical hairlines marking the dates of earnings announcements (accent), ownership inflections (red), and dividend ex-dates (faint). Hover any hairline for the event label.
Hover the chart for a date+price readout; click any vertical hairline to pin its event label.
| 2020 | — | |||
| 2019 | — | — | — | — |
| 2018 | — | — | — | — |
| 2017 | — | — | — | — |
One rupee invested at the start, plotted on a log scale, with closes back-adjusted for every stock split and bonus issue across the window. The headline reads the cumulative outcome; the CAGR badge annualises it.
Algorithmically-detected regime changes across the company's filings — promoter stake step-downs, FII threshold crossings, pledge emergence, EPS swings. Newest events first.
Foreign-institutional holding dropped from 40.00% to 0.42% — below the 25% mark in one quarter.
Every historical drawdown of 12% or more in the available 10 years of EOD data. The left bar shows depth; the right bar shows months until the price made a new all-time high.
Two views of recent event-driven price action: the earnings-reaction grid shows how the market traded the day after each of the last 8 quarterly results, and the insider heat strip shows weekly net insider buying/selling over the last 90 days.
| Date | Insider | Category | Type | Qty |
|---|
Equity prices and ratios are computed from NSE / BSE end-of-day data. No content on this page constitutes a buy / sell / hold recommendation. MintByte is an AMFI-registered mutual fund distributor (ARN-314872). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Not investment advice. Methodology · How we earn.
No signal at present — see methodology for the criteria.
No signal at present — see methodology for the criteria.
SWOT items are auto-derived from quantitative factor scores, Smart Money sentiment, and shareholding snapshot. They are not investment advice.
Foreign-institutional holding dropped from 40.00% to 0.42% — below the 35% mark in one quarter.
Foreign-institutional holding rose from 0.00% to 40.00% — past the 25% mark in one quarter.
Foreign-institutional holding rose from 0.00% to 40.00% — past the 35% mark in one quarter.
Algorithmically detected from quarterly shareholding + financial filings — rules documented in our methodology pages. Newest events at the top.
Each factor is computed monthly from the in-house model and bucketed into quintiles across the active equity universe. Q1 = top quintile on that factor (favourable position) · Q5 = bottom quintile.
Green stack = regular dividend per share · orange stack = specials/interims · dotted line = total indexed to first non-zero year (first=100).
T+1 = close one trading session after the result announcement (or next trading day).
| Value |
|---|
| 6 Jul 2024 | S Rajkumar | Promoters | SELL | 1,30,934 | ₹75L |
| 19 Jun 2024 | S Rajkumar | Promoters | SELL | 1,09,489 | ₹62L |
| 12 Mar 2024 | S Rajkumar | Promoters | SELL | 31,58,191 | ₹17Cr |
| 23 Dec 2023 | S Rajkumar | Promoters | PLEDGE REVOKE | 5,00,000 | ₹3Cr |
| 5 Dec 2023 | S Rajkumar | Promoters | SELL | 2,07,000 | ₹2Cr |
| 19 Jun 2023 | S Rajkumar | Promoters | BUY | 19,664 | ₹17L |
| 13 Jun 2023 | S Rajkumar | Promoters | BUY | 24,106 | ₹19L |
| 16 Apr 2022 | S Rajkumar | Promoters | PLEDGE | 36,82,307 | ₹3Cr |
| 31 Mar 2021 | DR. K.S RAMALINGAM | Director | BUY | 51,653 | ₹20L |
| 9 Mar 2021 | SANGEETHA SUNDARAMOORTHY | Promoters | BUY | 6,482 | ₹2L |
| 28 Dec 2020 | DR. K.S RAMALINGAM | Key Managerial Personnel | BUY | 64,306 | ₹20L |
| 18 Nov 2020 | SANGEETHA SUNDARAMOORTHY | Promoters | BUY | 6,200 | ₹2L |
| 17 Sept 2020 | DR. K.S RAMALINGAM | Employees/Designated Employees | BUY | 7,604 | ₹2L |
| 3 Mar 2020 | DR. KAVETHA SUNDARAMOORTHY | Promoters | BUY | 1,05,42,030 | ₹26Cr |
| 24 Feb 2020 | DR. KAVETHA SUNDARAMOORTHY | Promoters | BUY | 5,04,890 | ₹1Cr |